Interleukin-3 plays dual roles in osteoclastogenesis by promoting the development of osteoclast progenitors but inhibiting the osteoclastogenic process

Journal Article · Fri Nov 01 04:00:00 EDT 2013 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/J.BBRC.2013.09.098· OSTI ID:22242160

Hong, Huixian ^[1]; Shi, Zhenqi ^[2]; Qiao, Ping ^[2]; Li, Hui ^[3]; McCoy, Erin M. ^[2]; Mao, Ping ^[1]; Xu, Hui ^[3]; Feng, Xu ^[2]; Wang, Shunqing ^[1]

---

1. Department of Hematology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180 (China)
2. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294 (United States)
3. Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294 (United States)

Highlights: •IL-3 treatment of bone marrow cells generates a population of hematopoietic cells. •IL-3-dependent hematopoietic cells are capable of differentiating into osteoclasts. •Osteoclasts derived from IL-3-dependent hematopoietic cells are functional. •IL-3 promotes the development of osteoclast progenitors. •IL-3 inhibits the osteoclastogenic process. -- Abstract: Interleukin (IL)-3, a multilineage hematopoietic growth factor, is implicated in the regulation of osteoclastogenesis. However, the role of IL-3 in osteoclastogenesis remains controversial; whereas early studies showed that IL-3 stimulates osteoclastogenesis, recent investigations demonstrated that IL-3 inhibits osteoclast formation. The objective of this work is to further address the role of IL-3 in osteoclastogenesis. We found that IL-3 treatment of bone marrow cells generated a population of cells capable of differentiating into osteoclasts in tissue culture dishes in response to the stimulation of the monocyte/macrophage-colony stimulating factor (M-CSF) and the receptor activator of nuclear factor kappa B ligand (RANKL). The IL-3-dependent hematopoietic cells were able to further proliferate and differentiate in response to M-CSF stimulation and the resulting cells were also capable of forming osteoclasts with M-CSF and RANKL treatment. Interestingly, IL-3 inhibits M-CSF-/RANKL-induced differentiation of the IL-3-dependent hematopoietic cells into osteoclasts. The flow cytometry analysis indicates that while IL-3 treatment of bone marrow cells slightly affected the percentage of osteoclast precursors in the surviving populations, it considerably increased the percentage of osteoclast precursors in the populations after subsequent M-CSF treatment. Moreover, osteoclasts derived from IL-3-dependent hematopoietic cells were fully functional. Thus, we conclude that IL-3 plays dual roles in osteoclastogenesis by promoting the development of osteoclast progenitors but inhibiting the osteoclastogenic process. These findings provide a better understanding of the role of IL-3 in osteoclastogenesis.

• OSTI ID: 22242160
• Journal Information: Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 4 Vol. 440; ISSN BBRCA9; ISSN 0006-291X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
ACID PHOSPHATASE
BONE MARROW CELLS
CARBONIC ANHYDRASE
CATHEPSINS
CATTLE
ELECTROMECHANICS
GROWTH FACTORS
LIGANDS
MACROPHAGES
MICROSTRUCTURE
MONOCYTES
PHOSPHATES
POLYMERASE CHAIN REACTION
PRECURSOR
RECEPTORS
SCANNING ELECTRON MICROSCOPY
SKELETON
STEM CELLS
STIMULATION
TISSUE CULTURES
TRANSCRIPTION